AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2025
May 6, 2025
32407_dirs_2025-05-06_1adfa737-6c3f-41f4-8003-4feb75471a0c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-05-01
Reporting Person: Breedlove Robert Charles (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 50084 | Direct |
| Common Stock | 5108.4 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $15.21 | 2032-01-18 | Common Stock (12000) | Direct | |
| Stock Option (Right to Buy) | $8.35 | 2033-01-18 | Common Stock (13500) | Direct | |
| Stock Option (Right to Buy) | $7.6 | 2034-01-17 | Common Stock (15750) | Direct | |
| Stock Option (Right to Buy) | $5.76 | 2033-01-18 | Common Stock (15000) | Direct |
Footnotes
F1: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F2: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F3: The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F4: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.